On Remdesivir and Regeneron Monoclonal Antibody Treatments
October 3, 2020
The President is reported to have COVID-19 and to be receiving remdesivir and an investigational SARS-CoV-2 (virus causing COVID-19) neutralizing monoclonal antibody cocktail developed by Regeneron Pharmaceuticals. Many are wondering what this is all about.
Remdesivir is given to select hospitalized patients to reduce duration of symptoms in those with COVID-19. On September 16, 2020 Eli Lilly and Company, and on September 29, 2020 Regeneron Pharmaceuticals reported very early evidence of potential benefits of their respective SARS-CoV-2 monoclonal antibodies in outpatients with COVID-19.
There is little data supporting the use of the regimen being given to the President, and no data using these drugs in combination. Carefully conducted studies will ultimately define the safest and most effective way to manage outpatients with COVID-19. Although the circumstances are most unfortunate, they do provide an important call out for good science!!
Information on the novel coronavirus and the world's response to the COVID-19 pandemic is rapidly evolving. The following are links to interviews, presentations, and resources that the institute would like to highlight. Please check this section often as the materials available here will be updated frequently over the coming weeks.
Please visit the following health organizations for the most up-to-date information on possible vaccines, treatments, FAQs, news, and more: